Literature DB >> 32789243

Convalescent Rehabilitation for an Elderly Patient with Giant Cell Myocarditis: Case Report.

Hideki Arai1, Satoru Matsumoto1, Tomoyuki Morisawa2.   

Abstract

BACKGROUND: Giant cell myocarditis (GCM) is a rare inflammatory heart disease that, left untreated, rapidly progresses and is fatal without transplantation. Most patients with GCM die of congestive heart failure, but some survive for long periods, often after receiving immunosuppressive therapy. Although rehabilitation is crucial for improving activities of daily living (ADL) after discharge, no reports are available on the rehabilitation of patients with GCM. Here, we report the case of an elderly patient with GCM who was hospitalized for rehabilitation in the recovery phase. CASE: The patient was a 78-year-old woman who was hospitalized because of the exacerbation of chronic heart failure. She was diagnosed with GCM based on the histological findings. The patient was administered immunosuppressive therapy, and intra-aortic balloon pumping, percutaneous cardiopulmonary support, and artificial respiration were performed. Cardiac function gradually improved, and the patient was transferred to our hospital for convalescent rehabilitation. Rehabilitation, including calisthenics, upper and lower limb resistance training, walking, and endurance exercise on a bicycle ergometer, improved the patient's physical function, ADL, and cardiac function. DISCUSSION: Rehabilitation was safely and effectively conducted in a patient with GCM. This single report might be considered inadequate for ascertaining the efficacy of rehabilitation for patients with GCM, but it could be used as a reference when considering rehabilitation for other GCM patients. ©2018 The Japanese Association of Rehabilitation Medicine.

Entities:  

Keywords:  chronic heart failure; convalescent rehabilitation; giant cell myocarditis; immunosuppressive therapy

Year:  2018        PMID: 32789243      PMCID: PMC7365189          DOI: 10.2490/prm.20180018

Source DB:  PubMed          Journal:  Prog Rehabil Med        ISSN: 2432-1354


  6 in total

1.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology.

Authors:  Barry J Maron; James E Udelson; Robert O Bonow; Rick A Nishimura; Michael J Ackerman; N A Mark Estes; Leslie T Cooper; Mark S Link; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2015-11-02       Impact factor: 24.094

2.  Long-term outcome and its predictors in giant cell myocarditis.

Authors:  Kaj Ekström; Jukka Lehtonen; Riina Kandolin; Anne Räisänen-Sokolowski; Kaisa Salmenkivi; Markku Kupari
Journal:  Eur J Heart Fail       Date:  2016-07-13       Impact factor: 15.534

3.  Effects of exercise therapy on polymyositis complicated by post-myocarditis cardiomyopathy: A case report.

Authors:  Hidetoshi Yanagi; Naohisa Shindo
Journal:  J Rehabil Med       Date:  2017-03-06       Impact factor: 2.912

4.  Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.

Authors:  Riina Kandolin; Jukka Lehtonen; Kaisa Salmenkivi; Anne Räisänen-Sokolowski; Jyri Lommi; Markku Kupari
Journal:  Circ Heart Fail       Date:  2012-11-13       Impact factor: 8.790

5.  Usefulness of immunosuppression for giant cell myocarditis.

Authors:  Leslie T Cooper; Joshua M Hare; Henry D Tazelaar; William D Edwards; Randall C Starling; Mario C Deng; Santosh Menon; G Martin Mullen; Brian Jaski; Kent R Bailey; Madeleine W Cunningham; G William Dec
Journal:  Am J Cardiol       Date:  2008-09-18       Impact factor: 2.778

6.  Treatment of Fulminant Giant Cell Myocarditis Associated with Polymyositis Using a Left Ventricular Assist Device and Subsequent Corticosteroid and Immunosuppressive Therapy Leading to Remission.

Authors:  Junichi Ooka; Hidekazu Tanaka; Yutaka Hatani; Yukio Tsuji; Ryo Takeshige; Shumpei Mori; Kensuke Matsumoto; Shigeo Hara; Hiroshi Tanaka; Yutaka Okita; Ken-Ichi Hirata
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.